Patients perspectives on drug shortages in six European hospital settings - a cross sectional study / Darija Kuruc Poje, Domagoj Kifer, Isabelle Huys, Joao Miranda, Helena Jenzer, Nenad Miljković, Torsten Hoppe-Tichy, Marcin Bochniarz, Roberto Frontini, David G. Schwartz, Vesna Vujić-Aleksić, Lana Nežić, Eleni Rinaki, Leonidas Tzimis, Kim Green, Jelena Jovanić, Bojana Carić, Danijela Mandić, Katarina Vilić, Tomasz Bochenek, Vesna Bačić Vrca and Srećko Marušić
BACKGROUND: It is known that drug shortages represent a major challenge for all stakeholders involved in the process, but there is little evidence regarding insights into patients' awareness and perspectives. This study aimed to investigate the patients-perceived drug shortages experience and their view on outcomes in different European hospital settings. Furthermore, we wanted to explore information preferences on drug shortages. - METHODS: A retrospective, cross sectional, a mixed method study was conducted in six European hospital settings. One hospital (H) from each of this country agreed to participate: Bosnia and Herzegovina (H-BiH), Croatia (H-CR), Germany (H-GE), Greece (H-GR), Serbia (H-SE) and Poland (H-PO). Recruitment and data collection was conducted over 27 months from November 2017 until January 2020. Overall, we surveyed 607 patients which completed paper-based questionnaire. Questions related to: general information (demographic data), basic knowledge on drug shortages, drug shortages experienced during hospitalization and information preferences on drug shortage. Differences between hospital settings were analyzed using Chi-squared test or Fisher's exact test. For more complex contingency tables, Monte Carlo simulations (N = 2000) were applied for Fisher's test. Post-hoc hospital-wise analyses were performed using Fisher's exact tests. False discovery rate was controlled using the Bonferroni method. Analyses were performed using R: a language and environment for statistical computing (v 3.6.3). - RESULTS: 6 % of patients reported experiences with drug shortages while hospitalized which led to a deterioration of their health. The majority of affected patients were hospitalized at hematology and/or oncology wards in H-BiH, H-PO and H-GE. H-BiH had the highest number of affected patients (18.1 %, N = 19/105, p < 0.001) while the fewest patients were in H-SE (1 %, N = 1/100, p = 0.001). In addition, 82.5 %, (N = 501/607) of respondents wanted to be informed of alternative treatment options if there was a drug shortage without a generic substitute available. Majority of these patients (66.4 %, N = 386/501) prefer to be informed by a healthcare professional. - CONCLUSIONS: Although drug shortages led to serious medical consequences, our findings show that most of the patients did not perceive shortages as a problem. One possible interpretation is that good hospital management practices by healthcare professionals helped to mitigate the perceived impact of shortages. Our study highlights the importance of a good communication especially between patients and healthcare professionals in whom our patients have the greatest trust..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
12 July 2021 2021 |
---|---|
Erschienen: |
12 July 2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
BMC health services research - 21(2021), Artikel-ID 689, Seite 1-10 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kuruc Poje, Darija [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Cross-Sectional Studies |
---|
Anmerkungen: |
Gesehen am 16.09.2021 |
---|
Umfang: |
10 |
---|
doi: |
10.1186/s12913-021-06721-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
1770829334 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 1770829334 | ||
003 | DE-627 | ||
005 | 20230426195513.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210916s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12913-021-06721-9 |2 doi | |
035 | |a (DE-627)1770829334 | ||
035 | |a (DE-599)KXP1770829334 | ||
035 | |a (OCoLC)1341420943 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Kuruc Poje, Darija |e verfasserin |0 (DE-588)1241278075 |0 (DE-627)1770832017 |4 aut | |
245 | 1 | 0 | |a Patients perspectives on drug shortages in six European hospital settings - a cross sectional study |c Darija Kuruc Poje, Domagoj Kifer, Isabelle Huys, Joao Miranda, Helena Jenzer, Nenad Miljković, Torsten Hoppe-Tichy, Marcin Bochniarz, Roberto Frontini, David G. Schwartz, Vesna Vujić-Aleksić, Lana Nežić, Eleni Rinaki, Leonidas Tzimis, Kim Green, Jelena Jovanić, Bojana Carić, Danijela Mandić, Katarina Vilić, Tomasz Bochenek, Vesna Bačić Vrca and Srećko Marušić |
264 | 1 | |c 12 July 2021 | |
300 | |a 10 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Gesehen am 16.09.2021 | ||
520 | |a BACKGROUND: It is known that drug shortages represent a major challenge for all stakeholders involved in the process, but there is little evidence regarding insights into patients' awareness and perspectives. This study aimed to investigate the patients-perceived drug shortages experience and their view on outcomes in different European hospital settings. Furthermore, we wanted to explore information preferences on drug shortages. - METHODS: A retrospective, cross sectional, a mixed method study was conducted in six European hospital settings. One hospital (H) from each of this country agreed to participate: Bosnia and Herzegovina (H-BiH), Croatia (H-CR), Germany (H-GE), Greece (H-GR), Serbia (H-SE) and Poland (H-PO). Recruitment and data collection was conducted over 27 months from November 2017 until January 2020. Overall, we surveyed 607 patients which completed paper-based questionnaire. Questions related to: general information (demographic data), basic knowledge on drug shortages, drug shortages experienced during hospitalization and information preferences on drug shortage. Differences between hospital settings were analyzed using Chi-squared test or Fisher's exact test. For more complex contingency tables, Monte Carlo simulations (N = 2000) were applied for Fisher's test. Post-hoc hospital-wise analyses were performed using Fisher's exact tests. False discovery rate was controlled using the Bonferroni method. Analyses were performed using R: a language and environment for statistical computing (v 3.6.3). - RESULTS: 6 % of patients reported experiences with drug shortages while hospitalized which led to a deterioration of their health. The majority of affected patients were hospitalized at hematology and/or oncology wards in H-BiH, H-PO and H-GE. H-BiH had the highest number of affected patients (18.1 %, N = 19/105, p < 0.001) while the fewest patients were in H-SE (1 %, N = 1/100, p = 0.001). In addition, 82.5 %, (N = 501/607) of respondents wanted to be informed of alternative treatment options if there was a drug shortage without a generic substitute available. Majority of these patients (66.4 %, N = 386/501) prefer to be informed by a healthcare professional. - CONCLUSIONS: Although drug shortages led to serious medical consequences, our findings show that most of the patients did not perceive shortages as a problem. One possible interpretation is that good hospital management practices by healthcare professionals helped to mitigate the perceived impact of shortages. Our study highlights the importance of a good communication especially between patients and healthcare professionals in whom our patients have the greatest trust. | ||
650 | 4 | |a Cross-Sectional Studies | |
650 | 4 | |a Drug shortages | |
650 | 4 | |a Drugs, Generic | |
650 | 4 | |a Europe | |
650 | 4 | |a Germany | |
650 | 4 | |a Greece | |
650 | 4 | |a Hospital setting | |
650 | 4 | |a Hospitals | |
650 | 4 | |a Humans | |
650 | 4 | |a Patient safety | |
650 | 4 | |a Patients’ perspectives | |
650 | 4 | |a Poland | |
650 | 4 | |a Retrospective Studies | |
700 | 1 | |a Kifer, Domagoj |e verfasserin |4 aut | |
700 | 1 | |a Huys, Isabelle |e verfasserin |4 aut | |
700 | 1 | |a Miranda, Joao |e verfasserin |4 aut | |
700 | 1 | |a Jenzer, Helena |e verfasserin |4 aut | |
700 | 1 | |a Miljković, Nenad |e verfasserin |4 aut | |
700 | 1 | |a Hoppe-Tichy, Torsten |e verfasserin |0 (DE-588)1095801376 |0 (DE-627)856418919 |0 (DE-576)467814597 |4 aut | |
700 | 1 | |a Bochniarz, Marcin |e verfasserin |4 aut | |
700 | 1 | |a Frontini, Roberto |e verfasserin |4 aut | |
700 | 1 | |a Schwartz, David G. |e verfasserin |4 aut | |
700 | 1 | |a Vujić-Aleksić, Vesna |e verfasserin |4 aut | |
700 | 1 | |a Nežić, Lana |e verfasserin |4 aut | |
700 | 1 | |a Rinaki, Eleni |e verfasserin |4 aut | |
700 | 1 | |a Tzimis, Leonidas |e verfasserin |4 aut | |
700 | 1 | |a Green, Kim |e verfasserin |4 aut | |
700 | 1 | |a Jovanić, Jelena |e verfasserin |4 aut | |
700 | 1 | |a Carić, Bojana |e verfasserin |4 aut | |
700 | 1 | |a Mandić, Danijela |e verfasserin |4 aut | |
700 | 1 | |a Vilić, Katarina |e verfasserin |4 aut | |
700 | 1 | |a Bochenek, Tomasz |e verfasserin |4 aut | |
700 | 1 | |a Bačić Vrca, Vesna |e verfasserin |4 aut | |
700 | 1 | |a Marušić, Srećko |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC health services research |d London : BioMed Central, 2001 |g 21(2021), Artikel-ID 689, Seite 1-10 |h Online-Ressource |w (DE-627)331018756 |w (DE-600)2050434-2 |w (DE-576)107014920 |x 1472-6963 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2021 |g elocationid:689 |g pages:1-10 |g extent:10 |
856 | 4 | 0 | |u https://doi.org/10.1186/s12913-021-06721-9 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
936 | u | w | |d 21 |j 2021 |i 689 |h 1-10 |g 10 |
951 | |a AR | ||
952 | |d 21 |j 2021 |i 689 |h 1-10 |g 10 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 3978753227 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 16-09-21 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2021 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_22 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_10 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1537921967 |a Hoppe-Tichy, Torsten | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740686 |a Klinikum der Universität Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_7 |